A new genetic test called MammaPrint is helping many breast cancer patients. This test determines the risk of cancer ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Researchers have discovered a set of alterations in the structure and cellular makeup of breast connective tissue – known as ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

For Black women with HR–positive/ERBB2–negative breast cancer, a higher percentage of West African ancestry is associated ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

Weight gain combined with late first pregnancy (FP) or nulliparity is associated with an increased risk for breast cancer (BC ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, ...